Tampilan Petugas: Dataset related to article "Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity"

Dataset related to article "Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity"

Main Authors:	franzese, ciro, bonu, lorenzo marco, comito, tiziana, clerici, elena, loi, mauro, navarria, pierina, franceschini, davide, pressiani, tiziana, rimassa, lorenza, scorsetti, marta
Format:	info dataset Journal
Terbitan:	, 2020
Subjects:	Biliary tract cancer Cholangiocarcinoma Oligometastases Radiotherapy SABR SBRT Stereotactic body radiation therapy
Online Access:	https://zenodo.org/record/4425047

ctrlnum	4425047
fullrecord	<?xml version="1.0"?> <dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><creator>franzese, ciro</creator><creator>bonu, lorenzo marco</creator><creator>comito, tiziana</creator><creator>clerici, elena</creator><creator>loi, mauro</creator><creator>navarria, pierina</creator><creator>franceschini, davide</creator><creator>pressiani, tiziana</creator><creator>rimassa, lorenza</creator><creator>scorsetti, marta</creator><date>2020-12-22</date><description>This record contains raw data related to article “Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity" Introduction: Biliary tract cancers (BTC) are rare malignancies arising from biliary system. Systemic therapy is the cornerstone for stage IV disease, with poor overall survival (OS). Evidence is lacking about safety and efficacy of local ablative treatments, such as surgery and stereotactic body radiotherapy (SBRT) in the context of metastatic BTC (mBTC). Materials and methods: We retrospectively analyzed clinical outcomes for a cohort of mBTC patients treated with SBRT for oligometastatic disease. Inclusion criteria were 1-5 distant metastases; SBRT with a dose/fraction of a least 5 Gy to a biological effective dose (BED) of at least 40 Gy considering an α/β of 10 Gy. Analyzed outcomes included local control (LC), distant progression-free survival (DPFS), PFS, and OS. Results: 51 patients meeting the inclusion criteria. Primary tumor sites were intrahepatic cholangiocarcinoma (35%), extrahepatic cholangiocarcinoma (31%), ampullary adenocarcinoma (20%), gallbladder adenocarcinoma (14%). 21 patients were treated on liver lesions, 17 on nodal metastasis, 5 patients on lung lesions, 4 patients on recurrence along the extrahepatic bile duct. After a median follow-up of 14 months median OS was 13.7 months, 1- and 2-year OS were 58% and 41%, respectively. Node and lung as metastatic sites were associated with a longer OS (p < 0.001). Median LC was 26.8 months, and intrahepatic cholangiocarcinoma was associated with longer LC (p = 0.036). Median DPFS was 11 months, with 1- and 2-year DPFS of 48% and 27.8%, respectively. Ten patients reported grade 1-2 toxicity and 2 cases of acute G3 biliary obstruction. Conclusions: Stereotactic body radiotherapy (SBRT) is feasible in the context of mBTC. OS and PFS results are promising, considering that our patients were heavily pre-treated with systemic therapy. Patients with nodal or lung relapse have better prognosis. Distant relapses remain the main pattern of failure, but treatment of all metastatic sites seems to improve DMFS.</description><identifier>https://zenodo.org/record/4425047</identifier><identifier>10.5281/zenodo.4425047</identifier><identifier>oai:zenodo.org:4425047</identifier><relation>doi:10.1007/s00432-020-03285-9</relation><relation>pmid:32524292</relation><relation>doi:10.5281/zenodo.4384607</relation><relation>url:https://zenodo.org/communities/humanitasirccs</relation><rights>info:eu-repo/semantics/restrictedAccess</rights><subject>Biliary tract cancer</subject><subject>Cholangiocarcinoma</subject><subject>Oligometastases</subject><subject>Radiotherapy</subject><subject>SABR</subject><subject>SBRT</subject><subject>Stereotactic body radiation therapy</subject><title>Dataset related to article "Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity"</title><type>Other:info:eu-repo/semantics/other</type><type>Other:dataset</type><recordID>4425047</recordID></dc>
format	Other:info:eu-repo/semantics/other Other Other:dataset Journal:Journal Journal
author	franzese, ciro bonu, lorenzo marco comito, tiziana clerici, elena loi, mauro navarria, pierina franceschini, davide pressiani, tiziana rimassa, lorenza scorsetti, marta
title	Dataset related to article "Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity"
publishDate	2020
topic	Biliary tract cancer Cholangiocarcinoma Oligometastases Radiotherapy SABR SBRT Stereotactic body radiation therapy
url	https://zenodo.org/record/4425047
contents	This record contains raw data related to article “Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity" Introduction: Biliary tract cancers (BTC) are rare malignancies arising from biliary system. Systemic therapy is the cornerstone for stage IV disease, with poor overall survival (OS). Evidence is lacking about safety and efficacy of local ablative treatments, such as surgery and stereotactic body radiotherapy (SBRT) in the context of metastatic BTC (mBTC). Materials and methods: We retrospectively analyzed clinical outcomes for a cohort of mBTC patients treated with SBRT for oligometastatic disease. Inclusion criteria were 1-5 distant metastases; SBRT with a dose/fraction of a least 5 Gy to a biological effective dose (BED) of at least 40 Gy considering an α/β of 10 Gy. Analyzed outcomes included local control (LC), distant progression-free survival (DPFS), PFS, and OS. Results: 51 patients meeting the inclusion criteria. Primary tumor sites were intrahepatic cholangiocarcinoma (35%), extrahepatic cholangiocarcinoma (31%), ampullary adenocarcinoma (20%), gallbladder adenocarcinoma (14%). 21 patients were treated on liver lesions, 17 on nodal metastasis, 5 patients on lung lesions, 4 patients on recurrence along the extrahepatic bile duct. After a median follow-up of 14 months median OS was 13.7 months, 1- and 2-year OS were 58% and 41%, respectively. Node and lung as metastatic sites were associated with a longer OS (p < 0.001). Median LC was 26.8 months, and intrahepatic cholangiocarcinoma was associated with longer LC (p = 0.036). Median DPFS was 11 months, with 1- and 2-year DPFS of 48% and 27.8%, respectively. Ten patients reported grade 1-2 toxicity and 2 cases of acute G3 biliary obstruction. Conclusions: Stereotactic body radiotherapy (SBRT) is feasible in the context of mBTC. OS and PFS results are promising, considering that our patients were heavily pre-treated with systemic therapy. Patients with nodal or lung relapse have better prognosis. Distant relapses remain the main pattern of failure, but treatment of all metastatic sites seems to improve DMFS.
id	IOS16997.4425047
institution	ZAIN Publications
institution_id	7213
institution_type	library:special library
library	Cognizance Journal of Multidisciplinary Studies
library_id	5267
collection	Cognizance Journal of Multidisciplinary Studies
repository_id	16997
subject_area	Multidisciplinary
city	Stockholm
province	INTERNASIONAL
shared_to_ipusnas_str	1
repoId	IOS16997
first_indexed	2022-06-06T04:55:10Z
last_indexed	2022-06-06T04:55:10Z
recordtype	dc
_version_	1734903679448776704
score	17.608942

Dataset related to article "Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity"

Lihat Juga